TY - JOUR
T1 - Androgen-deprivation therapy in prostate cancer
T2 - A European expert panel review
AU - Schulman, Claude C.
AU - Irani, Jacques
AU - Morote, Juan
AU - Schalken, Jack A.
AU - Montorsi, Francesco
AU - Chlosta, Piotr L.
AU - Heidenreich, Axel
PY - 2010/10
Y1 - 2010/10
N2 - Context: Androgen-deprivation therapy (ADT) is the mainstay of treatment for metastatic prostate cancer and is also recommended in association with external-beam radiation therapy (EBRT) for patients with high-risk disease. Objective: Our aim was to make recommendations regarding optimal timing of ADT, target serum testosterone levels, intermittent ADT delivery, and quality of life (QoL) during ADT. Evidence acquisition: This review contains recommendations from a European expert panel held in May 2009. Evidence synthesis: There is ongoing debate over whether ADT should be initiated at diagnosis or delayed until biochemical or symptomatic progression. Immediate ADT is recommended for metastatic disease to defer symptom development and reduce serious complications. In node-positive disease or high-risk nonmetastatic disease unfit for curative therapy, immediate ADT is also an option. Furthermore, there is a clear benefit of adjuvant ADT in association with EBRT in patients with high-risk disease. Some retrospective evidence also supports adjuvant ADT use following radical prostatectomy for high-risk localised disease. In cases of biochemical relapse after definitive local therapy, early ADT may benefit patients with poor prognostic factors. For patients on ADT, the traditional
AB - Context: Androgen-deprivation therapy (ADT) is the mainstay of treatment for metastatic prostate cancer and is also recommended in association with external-beam radiation therapy (EBRT) for patients with high-risk disease. Objective: Our aim was to make recommendations regarding optimal timing of ADT, target serum testosterone levels, intermittent ADT delivery, and quality of life (QoL) during ADT. Evidence acquisition: This review contains recommendations from a European expert panel held in May 2009. Evidence synthesis: There is ongoing debate over whether ADT should be initiated at diagnosis or delayed until biochemical or symptomatic progression. Immediate ADT is recommended for metastatic disease to defer symptom development and reduce serious complications. In node-positive disease or high-risk nonmetastatic disease unfit for curative therapy, immediate ADT is also an option. Furthermore, there is a clear benefit of adjuvant ADT in association with EBRT in patients with high-risk disease. Some retrospective evidence also supports adjuvant ADT use following radical prostatectomy for high-risk localised disease. In cases of biochemical relapse after definitive local therapy, early ADT may benefit patients with poor prognostic factors. For patients on ADT, the traditional
KW - Androgen-deprivation therapy
KW - Hormonal therapy
KW - Intermittent therapy
KW - Luteinising hormone-releasing hormone agonist
KW - Prostate cancer
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=77956262445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956262445&partnerID=8YFLogxK
U2 - 10.1016/j.eursup.2010.07.001
DO - 10.1016/j.eursup.2010.07.001
M3 - Article
AN - SCOPUS:77956262445
VL - 9
SP - 675
EP - 691
JO - European Urology, Supplements
JF - European Urology, Supplements
SN - 1569-9056
IS - 7
ER -